Although hyperactivation of oncogenic RTK signaling in GBM tumors has been extensively appreciated, efforts in therapeutic targeting of single receptors such as EGFR and PDGFR have largely failed in clinical trials due to receptor-heterogeneity and redundancy. This evidence concerns the gene PDGFRB and glioblastoma.